Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

217.23 +1.80 (+0.84%)

Streaming Delayed Price Updated: 3:59 PM EDT, Sep 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

62 63 Next >

Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why ↗

April 24, 2024

Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA...

Via Benzinga

Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday? ↗

April 24, 2024

Rising Treasury yields have investors cautious despite positive news from the earnings season. The yield on the long-dated 30-year Treasury bond has surged to 4.79%. It’s on track to close at the...

Via Benzinga

Topics Bonds

Biogen (BIIB) Q1 2024 Earnings Call Transcript ↗

April 24, 2024

BIIB earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

Where Biogen Stands With Analysts ↗

April 11, 2024

Via Benzinga

Looking Into Biogen's Recent Short Interest ↗

April 03, 2024

Via Benzinga

Forecasting The Future: 18 Analyst Projections For Biogen ↗

March 25, 2024

Via Benzinga

Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings ↗

April 24, 2024

Biogen reports Q1 results: adjusted EPS $3.67 (beat consensus), sales $2.29 billion (missed consensus). Leqembi launch uptake triples, Zurzuvae's early trends encouraging.

Via Benzinga

BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024 ↗

April 24, 2024

BIIB stock results show that Biogen beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline? ↗

April 24, 2024

Biogen shares have lost nearly 40% of their value since last June. Could two key sales beats help revive shares?

Via Investor's Business Daily

Topics Earnings

Nasdaq Futures Get A Lift From Tesla, Texas Instruments Earnings: Analyst Points To Key Catalyst For Boosting Rally ↗

April 24, 2024

Nasdaq and S&P 500 futures signaled a higher open on Wednesday, thanks to upbeat guidance from EV giant Tesla, Inc. (NASDAQ:TSLA) and semiconductor m

Via Benzinga

A Closer Look at 21 Analyst Recommendations For Biogen ↗

March 05, 2024

Via Benzinga

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week ↗

April 21, 2024

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 09, 2024

Via Benzinga

10 Big-Name Stocks Near 52 Week Lows: Are They A Buy? ↗

March 29, 2024

Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week...

Via Talk Markets

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗

March 28, 2024

The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.

Via Investor's Business Daily

Tuesday Talk: Big-Tech Under Attack ↗

March 26, 2024

On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs.

Via Talk Markets

Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich ↗

March 25, 2024

Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.

Via InvestorPlace

European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab ↗

March 22, 2024

Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling.

Via Benzinga

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

March 21, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

March 20, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

March 19, 2024

Via Benzinga

10 Big-Name Stocks Near 52-Week Lows: Are They A Buy? ↗

March 16, 2024

Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week...

Via Talk Markets

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

March 14, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Fed Rate Cut Expectations Rise After February Jobs Report: Friday's Stock Movers ↗

March 08, 2024

February labor report shows mixed signals: increase in non-farm payrolls but higher unemployment rate and downward revisions. Wage growth lower than expected, fueling bets on Fed rate cuts. Stocks...

Via Benzinga

Topics Economy

Are These 5 Undervalued Stocks Ready to Break Out?

March 08, 2024

Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.

Via MarketBeat

Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision ↗

March 08, 2024

The FDA's upcoming advisory committee meeting on Eli Lilly's Phase 3 donanemab trial for early symptomatic Alzheimer's. Understand safety and efficacy considerations, with a delay in expected FDA...

Via Benzinga

FDA Delays Decision On Eli Lilly's Alzheimer Drug ↗

March 08, 2024

The FDA will hold an advisory panel for Lilly's Alzheimer drug donanemab.

Via Investor's Business Daily

Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers ↗

March 06, 2024

Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal...

Via Benzinga

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

March 06, 2024

From Biogen Inc.

Via GlobeNewswire

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

March 04, 2024

From Biogen Inc.

Via GlobeNewswire

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

62 63 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.